Document Detail


Gonadal function and fertility in male survivors treated for Hodgkin's disease in Iran.
MedLine Citation:
PMID:  17965791     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To investigate the effect of chemotherapy on gonadal function of young men cured of childhood Hodgkin's disease. METHODS: Young adult males surviving Hodgkin's disease, aged 17 and over at least 2 years after therapy were studied in Ali Asghar Children's Hospital, Tehran, Iran from March 2000 to March 2005. Clinical evaluation for secondary sexual characteristics, semen analysis, follicle stimulating hormone (FSH), luteinizing hormone (LH), and testosterone was studied in 33 survivors of Hodgkin's disease. RESULTS: The age at diagnosis was 5-15 years, median 9 years, age at study 17-29 years, median 19 years old. The median duration off therapy was 7 years (2-20 years). All 33 patients received chemotherapy as follows: 32 patients received nitrogen mustard (mechlorethamine), vincristine (Oncovin), procarbazine, prednisone (MOPP) / doxorubicin (adriamycin), bleomycin, vinblastine, dacarbazine (ABVD) 6-8 cycles, 5 of whom after relapses received other protocols. One received only MOPP. Twenty-seven (81.8%) had azoospermia, 2 had severe oligospermia, 3 had oligospermia, and one had normal sperm count (58000,000). All patients had normal secondary sexual characteristic. The FSH, and LH in 6/33 patients were above normal. Testosterone in 3/33 was below normal. CONCLUSION: A prepubertal status does not protect the gonads from the harmful effect of chemotherapy, and approximately 87% of male survivors of Hodgkin's disease develop azoospermia or severe oligospermia.
Authors:
Khadijeh A Rafsanjani; Mohammad Faranoush; Amir A Hedayatiasl; Parvaneh Vossough
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Saudi medical journal     Volume:  28     ISSN:  0379-5284     ISO Abbreviation:  Saudi Med J     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-10-29     Completed Date:  2008-02-21     Revised Date:  2008-06-23    
Medline Journal Info:
Nlm Unique ID:  7909441     Medline TA:  Saudi Med J     Country:  Saudi Arabia    
Other Details:
Languages:  eng     Pagination:  1690-3     Citation Subset:  IM    
Affiliation:
Department of Pediatric Hematology and Oncology, Iran University of Medical Sciences, Ali Asghar Children's Hospital, Semnan, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use
Azoospermia / chemically induced*
Follicle Stimulating Hormone / blood
Hodgkin Disease / drug therapy*
Humans
Iran
Luteinizing Hormone / blood
Male
Oligospermia / chemically induced*
Puberty
Sperm Count
Survivors*
Testosterone / blood
Chemical
Reg. No./Substance:
58-22-0/Testosterone; 9002-67-9/Luteinizing Hormone; 9002-68-0/Follicle Stimulating Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gender-related differences of risk factors among patients undergoing coronary artery bypass graft in...
Next Document:  Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic o...